Launched in 2007, the Innovative Medicines Initiative (IMI) aims to support
more efficient, earlier diagnostics and the development of better medicines
for patients by removing research bottlenecks in the drug development
pipeline. PREDECT, one of IMI’s new projects, is developing novel models for
breast, prostate and lung cancers. The Work Package 2 - coordinated by VTT
Technical Research Centre of Finland - focuses on target validation and
improved model systems for prostate cancer.
Being the largest public-private research partnership in the pharmaceutical
sector, IMI aims to speed up the development of better and safer medicines for
patients. IMI represents a unique joint undertaking between the research-based
pharmaceutical industry in Europe (Federation of Pharmaceutical Industries and
Associations; EFPIA) and the European Union.
of its 2nd call in 2010, IMI has recently announced the launch of 8 new
projects. One of these, PREDECT, will develop novel and technically advanced
in vivo and in vitro models for breast, prostate and lung cancers. Complex
next-generation cell culture models and experimental platforms attempt to more
closely mimic in vivo tumors, and a better dynamic reciprocity. These model
systems will be utilized to validate therapeutic targets, gain molecular
insights into therapy failure and tumor relapse, and develop novel therapeutic
strategies. The project is expected to shift paradigms in cell biology as well
as preclinical target validation, and achieve better prediction of drug
efficacy in patient cohorts.
Senior Research Scientist
Matthias Nees from VTT Technical Research Centre of Finland is coordinating
the Work Package 2, dedicated to target validation and improved model systems
for prostate cancer. This is a continuation of VTT’s strong activities in
cancer research and prostate cancer in particular.
is a partnership between 9 academic, 3 SME (Small and Medium Enterprise) and 7
EU pharmaceutical partners. The projects started in March 2011 and lasts for 5
years. Total project cost: 17.7 Million euros.
partners: AstraZeneca AB, Sweden; Bayer Schering Pharma AG, Germany;
Boehringer Ingelheim International GmbH, Germany; F. Hoffmann-La Roche AG,
Switzerland; Institut de Recherche Servier, France; Orion Pharma, Finland; and
Sigma-Tau S.p.A., Italy. Biomedicum Genomics Ltd, Finland; Oncotest GmbH,
Germany; IBET Institute of Experimental Biology and Technology, Portugal.
partners: VTT Technical Research Centre of Finland; Catholic University
Foundation, Netherlands; Erasmus University Medical Centre, Netherlands;
Institute of Cancer Research, United Kingdom; Ecole Polytechnique Fédérale de
Lausanne, Switzerland; Robert Bosch Society for Medical Research mbH, Germany;
University of Helsinki, Finland; University of Tartu, Estonia; Weizmann
Institute of Science, Israel.